NASDAQ:MYL - Mylan Stock Price, Price Target & More

Mylan trades on the NASDAQ under the ticker symbol "MYL."

Mylan NV (NASDAQ:MYL) announced its quarterly earnings results on Wednesday, May, 9th. The company reported $0.96 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.99 by $0.03. The company earned $2.68 billion during the quarter, compared to the consensus estimate of $2.74 billion. Mylan had a net margin of 6.04% and a return on equity of 18.56%. The business's quarterly revenue was down 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.93 EPS. View Mylan's Earnings History.

Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Mylan.

Mylan issued an update on its FY18 earnings guidance on Wednesday, May, 9th. The company provided EPS guidance of $5.20-5.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.37. The company issued revenue guidance of $11.75-13.25 billion, compared to the consensus revenue estimate of $12.43 billion.

19 brokerages have issued twelve-month price targets for Mylan's shares. Their predictions range from $29.39 to $59.00. On average, they expect Mylan's share price to reach $46.7047 in the next twelve months. This suggests a possible upside of 28.3% from the stock's current price. View Analyst Ratings for Mylan.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mylan in the last year. There are currently 6 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Mylan saw a drop in short interest during the month of June. As of June 29th, there was short interest totalling 11,394,932 shares, a drop of 33.0% from the June 15th total of 17,000,496 shares. Based on an average daily volume of 3,875,140 shares, the short-interest ratio is presently 2.9 days. Approximately 2.3% of the shares of the company are sold short. View Mylan's Current Options Chain.

Some companies that are related to Mylan include Celgene (CELG), Allergan (AGN), Shire (SHPG), Vertex Pharmaceuticals (VRTX), Zoetis (ZTS), Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), Shiseido (SSDOY), ASTELLAS PHARMA/ADR (ALPMY), Alexion Pharmaceuticals (ALXN), Teva Pharmaceutical Industries (TEVA), BioMarin Pharmaceutical (BMRN), UCB (UCBJF), GRIFOLS S A/S (GRFS) and Merck KGaA (MKGAF).

Media coverage about MYL stock has been trending somewhat negative on Tuesday, according to Accern Sentiment. The research firm rates the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mylan earned a coverage optimism score of -0.04 on Accern's scale. They also gave press coverage about the company an impact score of 43.63 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Mylan's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Hexavest Inc. (0.28%), Bank of Montreal Can (0.06%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%), Livforsakringsbolaget Skandia Omsesidigt (0.02%), Xact Kapitalforvaltning AB (0.02%) and Regent Investment Management LLC (0.01%). Company insiders that own Mylan stock include Anthony Mauro, Heather M Bresch, Laboratories Abbott, Paul Campbell, Rajiv Malik and Robert J Coury. View Institutional Ownership Trends for Mylan.

MYL stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Gateway Investment Advisers LLC. Company insiders that have sold Mylan company stock in the last year include Anthony Mauro, Heather M Bresch, Paul Campbell, Rajiv Malik and Robert J Coury. View Insider Buying and Selling for Mylan.

MYL stock was purchased by a variety of institutional investors in the last quarter, including Clinton Group Inc., Fjarde AP Fonden Fourth Swedish National Pension Fund, Regent Investment Management LLC, Xact Kapitalforvaltning AB, CENTRAL TRUST Co, Hexavest Inc. and Livforsakringsbolaget Skandia Omsesidigt. View Insider Buying and Selling for Mylan.

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MYL stock can currently be purchased for approximately $36.40.

Mylan has a market capitalization of $18.86 billion and generates $11.91 billion in revenue each year. The company earns $696 million in net income (profit) each year or $4.56 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected]